Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Fortress Biotech (FBIO) EBT Margin (2016 - 2025)

Fortress Biotech has reported EBT Margin over the past 12 years, most recently at 34.35% for Q4 2025.

  • Quarterly results put EBT Margin at 34.35% for Q4 2025, up 17218.0% from a year ago — trailing twelve months through Dec 2025 was 84.32% (up 12533.0% YoY), and the annual figure for FY2025 was 53.01%, up 16563.0%.
  • EBT Margin for Q4 2025 was 34.35% at Fortress Biotech, down from 50.21% in the prior quarter.
  • Over the last five years, EBT Margin for FBIO hit a ceiling of 50.21% in Q3 2025 and a floor of 27043.72% in Q2 2023.
  • Median EBT Margin over the past 5 years was 256.52% (2021), compared with a mean of 3036.57%.
  • Biggest five-year swings in EBT Margin: tumbled -1824372bps in 2023 and later soared 2686143bps in 2024.
  • Fortress Biotech's EBT Margin stood at 353.13% in 2021, then tumbled by -4334bps to 15658.24% in 2022, then surged by 100bps to 71.32% in 2023, then tumbled by -190bps to 206.53% in 2024, then surged by 83bps to 34.35% in 2025.
  • The last three reported values for EBT Margin were 34.35% (Q4 2025), 50.21% (Q3 2025), and 218.43% (Q2 2025) per Business Quant data.